MVision AI: your data is protected!
MVision AI not only provides unique AI-powered solutions for Radiotherapy treatment planning but also follows the highest standards of data protection for clinics and their patients. This is of utmost importance to us so we are very excited to celebrate Data Privacy Week and explain how we protect your data and respect patient privacy! From […]
Deep learning to generate synthetic CT Images from MR for Radiotherapy treatment planning
The generation of synthetic images has greatly advanced in recent years due to the progress of artificial intelligence. Some of the applications have recently been widely popularized in media, especially art and fashion generation and videos/photos creation of realistic-looking human faces¹. The image-to-image translation is a special case of synthetic image generation, where input images […]
NCCC Evaluation of MVision AI contouring software
S Warren, N Richmond MVision AI software has been under evaluation at NCCC (Newcastle upon Tyne Hospitals NHS Foundation Trust) since 28 February 2022* in order to: 1. compare AI contour quality and consistency with manual contouring; 2. estimate potential improvements in efficiency; 3. identify opportunities to improve clinical workflow. In the preliminary phase of […]
MVision: 2022 year in review
2022 came to an end. Seeing our names of customers, the number of scans and countries marked on the map, we know, we reached our accomplishments for 2022, because of uniqueness of our solution, the trust of our customers and the commitment of our team. Stepping into the year 2023, we hope to enjoy more […]
Distribution partnership agreement between MVision AI and Tecnosan
Finland, Helsinki, December 14, 2022 – MVision AI, the leading provider of AI-powered Guideline Based Segmentation solution for Radiotherapy planning and Tecnosan, advanced healthcare technology for radiotherapy and medical physics supplier in Italy announced cooperation and signing of a new Distribution partnership agreement. Both companies will closely cooperate on current and future projects to innovate […]
Cancer in Ireland – Raising Survival Rates
Every year, almost 45.000 people in Ireland are diagnosed with cancer, making Ireland the country with the highest cancer incidence in Europe. The 5 most diagnosed types of cancer in Ireland are: Skin cancer Prostate cancer Breast cancer Bowel cancer Lung cancer 1 out of 4 deaths in Ireland can be attributed to cancer, accounting […]
MVision’s GBS™ is Featured in 5 Posters at the German Society of Radiation Oncology (DEGRO) Annual Meeting
This week, we’re focusing on high-impact research presented during the German Society of Radiation Oncology (DEGRO) Annual Meeting. Five posters included a focus on MVision’s guideline-based segmentation, GBS™, solution (also available as an on-premise solution). Development of an AI-based auto-contouring of upper and lower jaw segments for optimized radiation planning and prosthetic rehabilitation of patients […]
Improving Tools to Fight Glioblastoma
Background Glioblastoma multiforme represents approximately half of the cases of central nervous system malignant tumors. The median age at diagnosis is 64 years, and the incidence was reported to be approximately 3 cases in 100 000 people. Genetic conditions, such as Li Fraumeni and Lynch Syndrome, are associated with a higher risk of glioblastoma occurrence. […]
RT for Prostate Cancer: Faster and Better – Is it Possible?
Background Worldwide, more than 1 400 000 men were diagnosed with prostate cancer in 2020, and it is estimated that one third will need radiotherapy during their treatment.
MVision AI Receives FDA 510(k) Clearance for Guideline-Based Segmentation Radiotherapy Software
Helsinki, 31st of May, 2022 – MVision AI announces that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for guideline-based, AI-powered software for automatic segmentation for radiotherapy.
Outcomes of SABR for Colorectal Cancer
Colorectal cancer (CRC) is one of the most common types of cancer diagnosed in the UK. About 41,000 people get cancer in the large bowel each year in the UK. In 2020, the WHO reported that colorectal cancer accounted for 10% of the cancers diagnosed annually. (Global Cancer Observatory) This article will bring to your […]
Indications and Effects of SABR for Renal Cancer
Renal cell carcinoma (RCC), generally referred to as Kidney Cancer, is among the ten most common cancers for men and women. The lifetime risk for developing RCC in men is about 1 in 46 and 1 in 80 for women. The American Cancer Society estimates about 79,000 new diagnoses and about 13,920 deaths from RCC […]
